[ad_1]
– New 44,000 square-foot fully integrated facility for development, manufacturing and testing of cell and gene therapies in Watertown, Massachusettsoffers end-to-end capabilities and one-stop manufacturing solutions –
WATERTOWN, Mass., Oct. 27, 2022 /PRNewswire/ — Landmark Bio™a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine, today announced the opening of its state-of-the-art full-spectrum development and biomanufacturing facility in Watertown.
“Landmark Bio is a unique venture bringing together the best of academia, industry, and research hospitals to translate groundbreaking research into life-changing therapies,” said Ran Zheng, chief executive officer of Landmark Bio.
“By fostering a strong cross-sector collaboration, we aim to solve three critical challenges in novel therapy development – capabilities, technology, and talent. We provide expertise in novel modality product design and development, innovative manufacturing technologies, in-house quality control . ..
Full story available on Benzinga.com
[ad_2]
Source link